Literature DB >> 1814531

Brain ubiquitin is markedly elevated in Alzheimer disease.

G P Wang1, S Khatoon, K Iqbal, I Grundke-Iqbal.   

Abstract

Levels of ubiquitin, microtubule associated protein tau and tubulin were determined by immunoassays in homogenates of cerebrum and cerebellum of Alzheimer disease and aged control cases. Ubiquitin levels increased many fold in the cerebral cortex of Alzheimer disease cases and the increase correlated strongly with the degree of neurofibrillary changes in the tissue. The increase in ubiquitin was much less remarkable in the cerebral white matter. Cerebellum which is unaffected with neurofibrillary changes in Alzheimer disease had normal levels of ubiquitin both in gray matter and in white matter. There was an appreciable increase in abnormally phosphorylated tau in an Alzheimer disease brain with severe neurofibrillary degeneration, whereas the normal tau levels were increased only slightly. Tubulin was slightly decreased in the cerebral gray matter but not in the adjacent white matter. Marked increase in brain ubiquitin in Alzheimer disease suggests the role of ubiquitin in the pathobiology of Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814531     DOI: 10.1016/0006-8993(91)91692-t

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

1.  Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases.

Authors:  Xin Wei; Lingjun Li
Journal:  Int J Clin Exp Pathol       Date:  2008-06-20

Review 2.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

3.  Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid.

Authors:  K N Prasad; F G La Rosa; J E Prasad
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-03       Impact factor: 2.416

Review 4.  Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

Authors:  Chia-Kwung Fan; Celia V Holland; Karen Loxton; Ursula Barghouth
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 5.  Proteomics in neurodegeneration--disease driven approaches.

Authors:  T Schulenborg; O Schmidt; A van Hall; H E Meyer; M Hamacher; K Marcus
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

6.  Relative sensitivity of undifferentiated and cyclic adenosine 3',5'-monophosphate-induced differentiated neuroblastoma cells to cyclosporin A: potential role of beta-amyloid and ubiquitin in neurotoxicity.

Authors:  A Kumar; A R Hovland; F G La Rosa; W C Cole; J E Prasad; K N Prasad
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

Review 7.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

8.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.

Authors:  Wen-Lin An; Richard F Cowburn; Lin Li; Heiko Braak; Irina Alafuzoff; Khalid Iqbal; Inge-Grundke Iqbal; Bengt Winblad; Jin-Jing Pei
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 9.  Developing pharmacological therapies for Alzheimer disease.

Authors:  K Iqbal; I Grundke-Iqbal
Journal:  Cell Mol Life Sci       Date:  2007-09       Impact factor: 9.261

Review 10.  Cerebrospinal fluid and blood biomarkers in Alzheimer's disease.

Authors:  Christian Humpel; Tanja Hochstrasser
Journal:  World J Psychiatry       Date:  2011-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.